Trade Names:Fosrenol- Tablets, chewable 500 mg- Tablets, chewable 750 mg- Tablets, chewable 1,000 mg
Inhibits GI absorption of phosphate by forming highly insoluble lanthanum phosphate complex with dietary phosphate released from food during digestion.
Very low absorption (bioavailability less than 0.002%). C max is 1 ng/mL. Administer with or immediately after food.
Highly bound to plasma proteins (more than 99%).
Not metabolized and not a substrate of CYP-450.
Elimination half-life is 53 h.
Reducing serum phosphate in patients with end-stage renal disease.
PO Initial dosage is 1,500 mg/day divided and taken with meals. Titrate dose every 2 to 3 wk, generally in increments of 750 mg/day, until acceptable serum phosphate level is reached.
Store tablets at controlled room temperature (59° to 86°F). Protect from moisture.
Do not take within 2 h of lanthanum.
None well documented.
Nausea (36%); vomiting (26%); diarrhea (23%); abdominal pain (17%); constipation (14%).
Dialysis graft complications (26%); dialysis graft occlusion (21%).
Category C .
Safety and efficacy not established.
No overall differences in safety and efficacy between patients 65 yr age and older compared with younger patients.
Use with caution in patients with acute peptic ulcer, ulcerative colitis, Crohn disease, or bowel obstruction because these populations were not included in clinical studies.
Abdominal x-ray patients taking lanthanum carbonate may have a radio-opaque appearance typical of an imaging agent.
There is no experience with overdosage.
Copyright © 2009 Wolters Kluwer Health.